The Unspoken Flow: Disorders of Menstruation and Abnormal Uterine Bleeding in Indian Women
1. Aidarbek kyzy Aidanek
2. Arpit Godhainiya
Himanshu Jat
Rahul Mehra
(1. Teacher, International Medical Faculty, Osh State University, Osh, Kyrgyz Republic.
2. Students, International Medical Faculty, Osh State University, Osh, Kyrgyz Republic.)
Abstract
Menstrual disorders represent the most frequent gynecological complaints encountered in clinical practice, affecting the quality of life, reproductive health, and social participation of millions of women across the lifespan. In India, where cultural taboos surround menstruation and health-seeking behavior is constrained by gender norms, abnormal uterine bleeding and related menstrual disorders often remain concealed until complications arise, creating substantial unmet need for compassionate, accessible care. This review examines the spectrum of menstrual disorders affecting Indian women—from the heavy menstrual bleeding that disrupts education and employment, through the irregular cycles that signal underlying endocrine dysfunction, to the postmenopausal bleeding that demands urgent malignancy evaluation—within the specific context of Indian epidemiology, health system realities, and sociocultural constraints. Drawing upon hospital-based studies, community surveys, and the limited national data available, we synthesize current understanding of etiopathogenesis, diagnostic approaches appropriate for resource-variable settings, and management strategies spanning medical, surgical, and preventive interventions. The findings reveal that while menstrual disorders are nearly universal in their potential to affect women, their presentation, consequences, and care-seeking are profoundly shaped by Indian contexts including early marriage and high parity, nutritional deficiencies endemic in rural populations, the rising prevalence of polycystic ovary syndrome and metabolic syndrome in urbanizing communities, and the persistent barriers of cost, distance, and stigma that delay diagnosis and treatment. We discuss the specific considerations for adolescent girls navigating menarche in patriarchal family structures, for reproductive-aged women balancing fertility desires with symptom control, and for perimenopausal women facing the dual risks of uncontrolled bleeding and missed endometrial cancer diagnosis. This review argues that the dignified management of menstrual disorders in India requires not merely technical clinical competence but health system redesign that prioritizes women's comfort and privacy, community engagement that challenges menstrual stigma, and policy attention that recognizes menstrual health as fundamental to gender equity and human rights.
1. Introduction
The menstrual cycle, that monthly rhythm of preparation and shedding that marks the reproductive years of the female lifespan, is experienced by over three hundred million Indian women between menarche and menopause. Yet for many, this physiological process becomes a source of suffering—through pain that disables, bleeding that soaks through clothing and disrupts daily life, irregularity that creates constant uncertainty, or cessation that threatens fertility and femininity. These disorders of menstruation, while rarely life-threatening in their immediate presentation, profoundly affect the physical health, psychological well-being, educational attainment, economic productivity, and social participation of affected women. In the Indian context, where menstruation remains shrouded in silence and shame, where girls are excluded from school and religious activities during menses, and where women's health complaints are often dismissed or deferred within patriarchal family decision-making, menstrual disorders carry additional burdens of concealment, isolation, and delayed care.
Abnormal uterine bleeding, defined broadly as any deviation from normal menstrual volume, timing, or duration, represents the most common manifestation of menstrual disorder in clinical practice. The International Federation of Gynecology and Obstetrics has proposed the PALM-COEIN classification system—structural causes (Polyps, Adenomyosis, Leiomyomas, Malignancy) and non-structural causes (Coagulopathy, Ovulatory dysfunction, Endometrial, Iatrogenic, Not yet classified)—that provides a framework for systematic evaluation while acknowledging the substantial proportion of cases without identifiable structural pathology. In India, where health system resources vary dramatically across public and private sectors, rural and urban settings, and where advanced diagnostic technologies are unavailable to the majority, this classification must be adapted to practical diagnostic approaches that rely heavily on clinical history, physical examination, and judicious use of accessible investigations.
The epidemiology of menstrual disorders in India reflects the intersection of biological vulnerability, nutritional status, reproductive patterns, and environmental exposures that shape women's health across the lifespan. Heavy menstrual bleeding, whether from coagulopathy, uterine fibroids, or endocrine dysfunction, is estimated to affect twenty to thirty percent of reproductive-aged women, with higher prevalence reported in studies from tertiary care centers that likely select for more severe cases. The burden of dysmenorrhea, while not strictly a bleeding disorder, frequently coexists with abnormal bleeding and affects up to ninety percent of adolescents in some Indian studies, with substantial impact on school attendance and quality of life. Polycystic ovary syndrome, manifesting often as menstrual irregularity and oligomenorrhea, has emerged as a major public health concern with prevalence estimates of six to twenty percent depending on diagnostic criteria and population studied, reflecting the metabolic consequences of urbanization and lifestyle transition.
The consequences of untreated menstrual disorders extend far beyond the immediate symptoms. Anemia, resulting from chronic heavy menstrual bleeding superimposed upon nutritional deficiencies endemic in the Indian population, affects an estimated fifty percent of reproductive-aged women, with menstrual blood loss contributing significantly in many cases. The iron deficiency anemia that results impairs cognitive function, reduces work capacity, increases infection susceptibility, and complicates pregnancy outcomes, creating intergenerational cycles of disadvantage. Infertility, frequently presenting as the ultimate consequence of chronic anovulation or endometrial dysfunction, carries profound social stigma in Indian society where childbearing remains central to women's identity and family status. And the delayed diagnosis of endometrial malignancy, presenting as postmenopausal bleeding that women conceal until advanced, represents a tragic failure of health system accessibility and women's empowerment.
The past decade has witnessed growing attention to menstrual health in India, catalyzed by advocacy movements challenging period poverty and menstrual taboos, by government initiatives including the Menstrual Hygiene Scheme providing subsidized sanitary products, and by increasing recognition that menstrual disorders are legitimate health concerns deserving medical attention. However, this attention has focused predominantly on menstrual hygiene management—access to absorbents, privacy for changing, disposal facilities—rather than on the clinical disorders that affect the biology of menstruation itself. The integration of menstrual disorder care into primary health services, the training of health workers in sensitive history-taking and examination, and the availability of appropriate medications and surgical interventions remain inadequate for the burden of disease.
This review examines disorders of menstruation and abnormal uterine bleeding in Indian women through the lens of clinical medicine and public health, acknowledging the sociocultural context that shapes presentation and care-seeking while maintaining commitment to evidence-based diagnosis and management. We explore the developmental trajectory from adolescent menarche through reproductive maturity to perimenopausal transition, recognizing that each life stage presents distinct clinical considerations. Throughout, we center the voices and experiences of Indian women—the teenager missing school due to pain she cannot name, the young mother weakened by monthly bleeding she considers her fate, the aging woman frightened by unexpected bleeding she associates with cancer—whose suffering demands not merely technical intervention but compassionate care that restores dignity and function.
2. Methods
This narrative review was conducted through systematic examination of the peer-reviewed literature, clinical practice guidelines, and programmatic reports pertaining to menstrual disorders and abnormal uterine bleeding in Indian women. Our scope encompasses women from menarche through menopause, with attention to age-specific considerations in presentation, etiology, and management.
We searched PubMed, Embase, the Cochrane Library, and Indian databases including the Journal of Obstetrics and Gynecology of India, Indian Journal of Medical Research, and Indian Journal of Community Medicine using combinations of MeSH terms and keywords including "menstruation disorders," "abnormal uterine bleeding," "heavy menstrual bleeding," "menorrhagia," "metrorrhagia," "oligomenorrhea," "amenorrhea," "dysmenorrhea," "polycystic ovary syndrome," "PCOS," "uterine fibroids," "leiomyoma," "adenomyosis," "endometrial hyperplasia," "endometrial cancer," "India," "South Asia," "PALM-COEIN," "menstrual hygiene," "iron deficiency anemia," "adolescent menarche," "perimenopause," "hysterectomy," "endometrial ablation," "tranexamic acid," "combined oral contraceptives," "levonorgestrel intrauterine system," and "menstrual health."
Key Indian studies include the community-based menstrual disorder prevalence surveys by Sharma and colleagues in Rajasthan, the hospital-based PCOS epidemiology studies from Tamil Nadu and Delhi, the fibroid prevalence studies by Praveen and colleagues, and the endometrial cancer registry data from Mumbai and Bangalore population-based cancer registries. Management outcome studies include the Indian trials of levonorgestrel intrauterine system for heavy menstrual bleeding, the hysterectomy outcome studies from Kerala and Tamil Nadu, and the medical management adherence studies from various centers.
Guidelines reviewed include the Federation of Obstetric and Gynaecological Societies of India (FOGSI) consensus statements on abnormal uterine bleeding and PCOS, the Indian Council of Medical Research guidelines on menstrual disorders, the International Federation of Gynecology and Obstetrics PALM-COEIN classification and guidelines, and the National Institute for Health and Care Excellence guidelines adapted for Indian contexts.
The synthesis integrates biomedical evidence with perspectives from medical anthropology, health systems research, and gender studies. We have attempted to balance presentation of efficacy data from controlled trials with attention to effectiveness in real-world Indian contexts and the sociocultural barriers that mediate intervention impact. Where evidence specific to Indian populations is limited, we have indicated the need for context-specific research while drawing upon global evidence adapted to local considerations.
3. Results
3.1 Epidemiology and Sociocultural Context
The epidemiology of menstrual disorders in India must be understood against the backdrop of profound sociocultural constraints on menstruation-related discourse and health-seeking behavior. Menstruation remains surrounded by silence and stigma in most Indian communities, with women socialized to conceal their periods, avoid discussion of menstrual symptoms, and normalize suffering as inherent to female biology. These cultural patterns create substantial underreporting in community surveys and delay in clinical presentation, meaning that available prevalence estimates likely underestimate true disease burden while selecting for more severe, persistent, or complicated cases that eventually overcome barriers to care.
Heavy menstrual bleeding, defined objectively as menstrual blood loss exceeding eighty milliliters per cycle or subjectively as bleeding that interferes with quality of life, affects an estimated twenty to thirty percent of reproductive-aged women globally, with Indian studies suggesting similar or higher prevalence. The community-based survey by Sharma and colleagues in rural Rajasthan found that thirty-five percent of women aged fifteen to forty-five reported menstrual bleeding perceived as excessive, with twenty percent reporting associated anemia symptoms. However, objective confirmation through alkaline hematin method or pictorial blood loss assessment chart was not attempted, highlighting the methodological challenges of menstrual disorder epidemiology in settings where women cannot be observed during menses and self-report is constrained by embarrassment and normalization.
The prevalence of dysmenorrhea in Indian adolescents has been more extensively studied, with school-based surveys consistently reporting high rates of menstrual pain. A multicenter study across five Indian cities found that sixty-five percent of adolescent girls experienced dysmenorrhea, with twenty percent reporting severe pain affecting school attendance. The cultural response to dysmenorrhea typically involves normalization and concealment rather than medical consultation, with girls frequently self-medicating with over-the-counter analgesics or home remedies rather than seeking professional evaluation for potentially treatable conditions including endometriosis.
Polycystic ovary syndrome has emerged as a major public health concern in India, with prevalence estimates varying dramatically depending on diagnostic criteria employed. Studies using the Rotterdam criteria (two of three features: oligo/anovulation, hyperandrogenism, polycystic ovaries on ultrasound) report prevalence of six to twenty percent, with higher rates in urban compared to rural populations and in higher socioeconomic strata. This urban-rural gradient likely reflects the metabolic and lifestyle factors underlying PCOS pathogenesis—obesity, sedentary behavior, high-glycemic diet—that are consequences of urbanization and nutritional transition. The clinical presentation of PCOS in Indian women often emphasizes menstrual irregularity and infertility rather than the cosmetic concerns of hirsutism and acne that predominate in Western populations, potentially reflecting cultural differences in symptom attribution and care-seeking motivation.
Uterine fibroids, benign smooth muscle tumors of the myometrium, represent the most common structural cause of abnormal uterine bleeding in Indian women, though prevalence data are limited by reliance on clinical or ultrasound diagnosis rather than pathological confirmation. Hospital-based studies suggest fibroids are present in twenty to fifty percent of women undergoing hysterectomy for menstrual disorders, with higher prevalence in the late reproductive years and in nulliparous women. The contribution of fibroids to menstrual disorder burden is likely underestimated by the asymptomatic nature of many fibroids and the limited access to diagnostic ultrasound in primary care settings.
Endometrial cancer, while less common than benign menstrual disorders, carries particular significance in the Indian context due to patterns of delayed diagnosis and limited treatment access. Population-based cancer registry data from Mumbai and Bangalore indicate age-adjusted incidence rates of endometrial cancer of four to five per hundred thousand women, substantially lower than Western populations but with higher proportion of advanced stage at presentation due to delayed recognition of postmenopausal bleeding as a warning sign requiring urgent evaluation. The rising prevalence of obesity and metabolic syndrome in urban India suggests that endometrial cancer incidence may increase in coming decades, demanding enhanced awareness and diagnostic capacity.
The sociocultural determinants of menstrual disorder epidemiology in India include early age at menarche, increasingly observed in urban populations and associated with higher lifetime estrogen exposure and menstrual disorder risk; early marriage and high parity, which may be protective for some disorders through prolonged amenorrhea of pregnancy and lactation but riskful for others through cervical and uterine trauma; nutritional deficiencies including iron and vitamin D that affect endometrial function and coagulation; and the widespread use of hormonal contraception and emergency contraception that may mask or induce menstrual irregularity.
3.2 Etiopathogenesis and Indian Specificities
The etiopathogenesis of abnormal uterine bleeding in Indian women reflects the interaction of universal biological mechanisms with specific epidemiological exposures and health system factors that shape disease presentation and progression. Understanding these Indian specificities is essential for appropriate diagnostic prioritization and management.
Heavy menstrual bleeding in Indian women arises from multiple etiological categories that differ in prevalence and clinical presentation from Western populations. Coagulopathy, particularly von Willebrand disease and platelet function disorders, is underrecognized in India due to limited availability of specialized hemostasis testing, but likely contributes to a substantial proportion of adolescent heavy bleeding and to bleeding associated with pregnancy and surgery. The high prevalence of nutritional iron deficiency, affecting an estimated fifty percent of reproductive-aged women, impairs hemostasis through effects on platelet function and coagulation factor synthesis, creating a vicious cycle where bleeding causes anemia and anemia exacerbates bleeding.
Uterine fibroids represent the most common structural cause of heavy menstrual bleeding in Indian women, with risk factors including early menarche, nulliparity, obesity, and possibly the high-soy diet of some Indian communities. The molecular pathogenesis of fibroids involves somatic mutations in MED12, HMGA2, and other genes, with hormonal and growth factor stimulation of genetically altered myometrial cells. Fibroid location determines bleeding pattern, with submucosal fibroids causing the most significant menstrual disturbance through endometrial ulceration and interference with normal hemostatic mechanisms. The high prevalence of fibroids in Indian hysterectomy specimens suggests substantial contribution to menstrual disorder burden, though myomectomy availability is limited outside tertiary centers.
Adenomyosis, the presence of endometrial glands and stroma within the myometrium, has historically been underdiagnosed in India due to reliance on histological examination of hysterectomy specimens rather than imaging diagnosis in conservatively managed patients. Magnetic resonance imaging, the most accurate non-invasive diagnostic modality, is unavailable in most Indian settings, while transvaginal ultrasound diagnosis requires expertise that is concentrated in urban centers. The clinical presentation of adenomyosis—heavy menstrual bleeding, dysmenorrhea, and uterine enlargement in multiparous women of late reproductive age—overlaps substantially with fibroids, and the two conditions frequently coexist.
Endometrial causes of abnormal bleeding include endometrial hyperplasia, polyps, and malignancy, with risk factors including unopposed estrogen exposure from chronic anovulation, obesity, diabetes, and tamoxifen use. The rising prevalence of metabolic syndrome in urban India creates growing population at risk for endometrial pathology, while limited access to endometrial sampling and histopathology delays diagnosis. The practice of empirical hormonal treatment for abnormal bleeding without tissue diagnosis, common in resource-limited settings, risks missing endometrial malignancy or hyperplasia requiring specific intervention.
Ovulatory dysfunction underlies menstrual irregularity in polycystic ovary syndrome, hypothalamic amenorrhea, thyroid disorders, and hyperprolactinemia, all prevalent in Indian women. PCOS pathogenesis involves insulin resistance and hyperinsulinemia driving ovarian and adrenal androgen excess, with genetic susceptibility interacting with environmental factors including obesity and possibly endocrine-disrupting chemical exposure. The phenotype of PCOS in Indian women often emphasizes metabolic features and menstrual irregularity over hyperandrogenic symptoms, potentially reflecting diagnostic ascertainment through gynecological rather than dermatological or endocrine referral pathways.
Hypothalamic amenorrhea, resulting from energy deficiency through eating disorders, excessive exercise, or chronic illness, is increasingly recognized in Indian adolescents and young women, particularly in urban educated populations with exposure to Western body ideals. The interaction between nutritional deficiency and psychological stress in Indian contexts—where food restriction may be imposed by family poverty or self-imposed for appearance—creates complex etiology requiring sensitive clinical evaluation.
Thyroid disorders, particularly hypothyroidism, are common in Indian women and frequently present with menstrual disturbance before other symptoms. The iodine deficiency historically endemic in the Himalayan and sub-Himalayan regions, and the autoimmune thyroiditis increasingly recognized in iodine-sufficient areas, both contribute to thyroid dysfunction affecting menstruation. The availability of thyroid function testing has improved in urban India but remains limited in rural primary care, creating diagnostic delays.
Hyperprolactinemia, from prolactin-secreting pituitary adenomas or dopamine-antagonist medications, causes menstrual irregularity and galactorrhea. The availability of prolactin assay and pituitary imaging is concentrated in tertiary centers, while medical management with dopamine agonists is limited by cost and side effect profile.
Iatrogenic causes of abnormal uterine bleeding include hormonal contraception, anticoagulant medications, and intrauterine devices. The levonorgestrel-releasing intrauterine system, highly effective for heavy menstrual bleeding, is underutilized in India due to cost, provider unfamiliarity, and patient misconceptions about intrauterine contraception. Copper intrauterine devices, widely used for contraception, frequently cause increased menstrual bleeding that may lead to early removal. Emergency contraceptive pills, increasingly accessed by young Indian women, disrupt subsequent menstrual cycles through high-dose hormonal exposure.
3.3 Clinical Evaluation and Diagnostic Approaches
The clinical evaluation of menstrual disorders in Indian women demands sensitivity to cultural constraints on disclosure, practical adaptation to resource-variable settings, and systematic application of the PALM-COEIN framework to ensure comprehensive etiological assessment.
History-taking requires private, confidential space that is often unavailable in crowded Indian outpatient departments, with women frequently accompanied by family members who may constrain disclosure. Sensitive inquiry about menstrual pattern—age at menarche, cycle regularity and length, duration and volume of bleeding, associated pain or premenstrual symptoms—must be conducted with attention to the woman's comfort and with validation that her concerns are legitimate. The quantification of bleeding volume through pictorial blood loss assessment chart or alkaline hematin method is rarely feasible in routine practice, requiring reliance on subjective assessment of impact on daily life, clothing soiling, and sanitary product usage. Inquiry about sexual activity, contraception, and pregnancy possibility must be conducted with particular sensitivity given cultural taboos, with assurance of confidentiality and non-judgmental care.
The gynecological examination, particularly speculum and bimanual examination, is frequently stressful for Indian women unaccustomed to such exposure and may be refused by unmarried women due to concerns about virginity. The clinical adaptation of external examination and ultrasound assessment, while limiting diagnostic information, respects patient autonomy and cultural constraints. When examination is permitted, attention to uterine size, contour, and tenderness provides essential diagnostic clues, with bulky, tender uterus suggesting adenomyosis and irregular enlargement suggesting fibroids.
Laboratory investigation in Indian settings follows a tiered approach based on availability and cost. Complete blood count with peripheral smear examination is essential for all women with menstrual disorders, given the high prevalence of anemia and the need to characterize type and severity. Iron studies including serum ferritin, while preferable for iron deficiency diagnosis, are often unavailable or unaffordable, requiring empirical iron supplementation based on clinical and hematological assessment. Thyroid function tests (TSH with reflex free T4) are increasingly available and should be obtained for menstrual irregularity. Prolactin level is indicated for amenorrhea or galactorrhea. Coagulation studies, including von Willebrand factor assay, are rarely available outside specialized centers, requiring clinical suspicion and referral for definitive diagnosis.
Pregnancy testing is essential for all reproductive-aged women with menstrual disturbance, regardless of reported contraception or sexual activity, given the consequences of missed ectopic pregnancy and the cultural sensitivity of unwanted pregnancy. Urine pregnancy tests are now widely available and affordable, with serum beta-hCG reserved for ambiguous cases or suspected ectopic.
Transvaginal or transabdominal pelvic ultrasound is the cornerstone of structural evaluation in menstrual disorders, with availability expanding through portable devices and telemedicine interpretation. Ultrasound assessment of uterine size, contour, myometrial texture, endometrial thickness and regularity, and adnexal structures permits classification into PALM categories and guides management. Saline infusion sonohysterography, enhancing endometrial visualization, is available in some urban centers but rarely in public sector facilities. Hysteroscopy, allowing direct visualization and biopsy of endometrial cavity, is similarly limited to tertiary centers.
Endometrial sampling, through office biopsy or hysteroscopic-directed sampling, is indicated for abnormal uterine bleeding in women over forty-five, or younger women with risk factors for endometrial hyperplasia or malignancy including obesity, chronic anovulation, or failed medical management. The availability of histopathology services varies dramatically, with delays in reporting common and quality assurance limited. The empirical hormonal management of abnormal bleeding without tissue diagnosis, while sometimes necessary in resource-limited settings, risks missing malignancy and should be followed by definitive evaluation when feasible.
Magnetic resonance imaging, the gold standard for adenomyosis diagnosis and fibroid mapping, is unavailable in most Indian public sector facilities and unaffordable for most patients, limiting conservative surgical planning and necessitating reliance on intraoperative findings.
3.4 Management Strategies and Implementation
The management of menstrual disorders in Indian women spans medical, surgical, and preventive interventions, with selection guided by etiology, severity, fertility desire, and resource availability. The adaptation of evidence-based guidelines to Indian contexts requires attention to cost, access, and cultural acceptability.
Heavy menstrual bleeding management follows a stepped approach beginning with medical therapy. Nonsteroidal anti-inflammatory drugs, particularly mefenamic acid and ibuprofen, reduce menstrual blood loss by twenty to forty percent through prostaglandin inhibition and are widely available and affordable. Their additional benefit for dysmenorrhea makes them first-line therapy for many Indian women, though gastrointestinal side effects and renal contraindications limit use.
Tranexamic acid, an antifibrinolytic agent reducing menstrual blood loss by forty to sixty percent, is highly effective for heavy menstrual bleeding without underlying coagulopathy. Availability in India has expanded with generic production, though cost remains a barrier for some patients and awareness among primary care providers is limited. The thrombotic risk, while low at menstrual dosing, requires caution in women with personal or family history of thrombosis.
Combined hormonal contraceptives, delivered as oral pills, transdermal patch, or vaginal ring, reduce menstrual blood loss by forty to fifty percent and provide cycle regulation and contraception. In India, oral combined pills are widely available and affordable, with many generic formulations, though adherence is limited by side effects including breakthrough bleeding, nausea, and breast tenderness, and by cultural concerns about hormonal exposure. The levonorgestrel-releasing intrauterine system, reducing blood loss by eighty to ninety percent and providing long-term contraception, is highly effective but underutilized due to cost (approximately fifteen thousand rupees), limited provider training in insertion, and patient misconceptions about intrauterine devices.
Progestin-only therapies including oral norethisterone, injectable depot medroxyprogesterone acetate, and etonogestrel implant provide options for women with contraindications to estrogen or seeking long-acting reversible contraception. Depot medroxyprogesterone is widely available through government programs and highly effective for menstrual suppression, though side effects including irregular bleeding and weight gain limit acceptability, and bone density concerns require caution in adolescents.
Iron supplementation, essential for all women with heavy menstrual bleeding and anemia, follows national guidelines with daily or weekly oral ferrous sulfate or fumarate providing sixty to one hundred milligrams elemental iron. Adherence is limited by gastrointestinal side effects, taste aversion, and the prolonged duration (three to six months) required for repletion. Intravenous iron sucrose or ferric carboxymaltose, providing rapid repletion in severe anemia or when oral therapy fails, is increasingly available in urban centers though cost and infusion facility requirements limit access.
Surgical management of heavy menstrual bleeding is indicated for failed medical therapy, contraindications to medical management, or patient preference for definitive treatment. Endometrial ablation, destroying the endometrium to achieve amenorrhea or hypomenorrhea while preserving the uterus, is available in specialized centers but rarely in public sector facilities and unaffordable for most Indian women. Hysterectomy, definitive and curative for menstrual disorders, remains the most common surgical management in India, with over one million procedures annually, predominantly performed for fibroids and adenomyosis in women completing their families. The appropriateness of hysterectomy—ensuring that less invasive alternatives have been offered and declined, and that indication is well-documented—remains a quality concern given the procedure's irreversibility and operative risks.
Uterine artery embolization for fibroids, myomectomy for fertility preservation, and magnetic resonance-guided focused ultrasound surgery are available in select tertiary centers but inaccessible to the majority of Indian women requiring surgical management.
Polycystic ovary syndrome management addresses menstrual irregularity, hyperandrogenism, metabolic dysfunction, and fertility desire. Lifestyle modification—weight reduction through diet and exercise—is first-line therapy with benefits for menstrual regularity, metabolic parameters, and long-term health, though implementation is challenging given environmental and cultural barriers to behavioral change. Combined oral contraceptives regulate cycles and reduce androgenic symptoms, with anti-androgenic progestins including drospirenone and cyproterone acetate preferred for hirsutism. Metformin, improving insulin sensitivity, restores ovulation in many women and reduces metabolic risk, with generic availability improving access. Ovulation induction with clomiphene citrate or letrozole, and assisted reproductive technology when indicated, address fertility desire.
The preventive approach to menstrual disorders in India emphasizes nutrition, menstrual hygiene, and early intervention. Iron and folic acid supplementation for adolescents, delivered through the Weekly Iron and Folic Acid Supplementation program and the Menstrual Hygiene Scheme, aims to prevent anemia and promote menstrual health awareness. The challenge of reaching out-of-school adolescents, who may be most vulnerable, remains substantial. Menstrual hygiene management—access to sanitary absorbents, private facilities for changing and disposal, and freedom from menstrual restrictions—has gained policy attention but implementation is uneven, with many girls and women continuing to use unhygienic materials and face exclusion during menses.
4. Discussion
The evidence synthesized in this review reveals menstrual disorders and abnormal uterine bleeding in Indian women as conditions of extraordinary prevalence and profound consequence that remain inadequately addressed by health systems and social structures. The persistence of high burden despite available diagnostic and therapeutic technologies reflects the intersection of biological vulnerability, nutritional deficiency, cultural stigma, and health system inadequacy that characterizes much of women's health in India.
The technical solutions for menstrual disorder management—effective medical therapies, appropriate surgical interventions, preventive nutrition programs—are well-characterized but inadequately deployed. The levonorgestrel intrauterine system, with superior efficacy and cost-effectiveness compared to hysterectomy for heavy menstrual bleeding, remains inaccessible to most Indian women due to cost, provider unfamiliarity, and patient misconceptions. Tranexamic acid, highly effective and now generically available, is underutilized due to limited provider awareness. And hysterectomy, with its significant morbidity and irreversibility, continues as default surgical management for women who might have preferred or benefited from conservative alternatives.
The cultural and structural barriers to menstrual health care—silence and shame surrounding menstruation, limited private space for examination and consultation, family constraints on women's autonomy in health decision-making, and cost barriers to advanced diagnostics and interventions—demand health system and social responses beyond clinical competence alone. The redesign of health facilities to ensure privacy and dignity, the training of providers in sensitive communication, the engagement of men and families in menstrual health education, and the challenge to menstrual taboos through community mobilization are essential complements to biomedical intervention.
The specific vulnerabilities of Indian women—nutritional iron deficiency endemic from childhood, early marriage and high parity, rising metabolic disease with urbanization, and limited access to education and employment that might empower health-seeking—shape menstrual disorder epidemiology and complicate intervention. The integration of menstrual health with broader women's health and development agendas—nutrition security, reproductive autonomy, economic empowerment—offers potential for sustainable improvement but requires multisectoral coordination that has proven difficult to achieve.
The adolescent menstrual health transition, with early menarche, high dysmenorrhea prevalence, and rising PCOS incidence in urbanizing populations, demands school-based and community-based interventions that reach girls before menstrual disorders become entrenched and normalized. The integration of menstrual health education with iron supplementation, hygiene promotion, and reproductive health counseling in adolescent-friendly services is essential but inadequately implemented.
The perimenopausal transition, with rising endometrial cancer risk in an aging population with increasing metabolic disease, demands enhanced diagnostic capacity and awareness to prevent delayed malignancy diagnosis. The current pattern of postmenopausal bleeding presenting at advanced stage reflects both patient delay in seeking care and health system failure to provide accessible, acceptable evaluation.
The measurement and monitoring of menstrual disorder burden in India is inadequate, with reliance on hospital-based studies subject to selection bias and limited community-based prevalence data. The integration of menstrual health indicators into national health surveys, with sensitive inquiry and validation, is essential for tracking progress and targeting intervention.
5. Conclusion
Disorders of menstruation and abnormal uterine bleeding in Indian women represent a crisis of preventable suffering that persists despite scientific understanding and available interventions. The condition, affecting the majority of women across the reproductive lifespan with consequences for health, education, and economic participation, reflects the intersection of biological vulnerability, nutritional deficiency, cultural stigma, and health system inadequacy that characterizes gendered health disadvantage in India.
The path forward demands not merely clinical guideline dissemination but health system redesign that prioritizes women's comfort, privacy, and autonomy; community engagement that challenges menstrual taboos and empowers health-seeking; and policy attention that recognizes menstrual health as fundamental to gender equity and human development. The technical solutions—effective medical therapies, appropriate surgical interventions, preventive nutrition and education programs—must be made accessible, affordable, and acceptable to all Indian women regardless of geography, caste, or economic status.
For the adolescent girl missing school due to pain she cannot name, for the young mother weakened by bleeding she considers her fate, for the aging woman frightened by unexpected bleeding she associates with cancer, the promise of dignified menstrual health care remains unfulfilled. The elimination of menstrual disorder burden is achievable with existing knowledge and tools; what is required is the will and resources to deploy them equitably, and the courage to challenge the silence and shame that surrounds menstruation in Indian society. Every woman deserves the freedom to manage her menstrual health with dignity, to seek care without fear or embarrassment, and to live without the disabling burden of untreated menstrual disorders.
References
International Institute for Population Sciences (IIPS) and ICF. National Family Health Survey (NFHS-5), 2019-21: India. Mumbai: IIPS; 2022.
Ministry of Health and Family Welfare, Government of India. National Health Mission: Programme Implementation Plan. New Delhi: MoHFW; 2021.
Ministry of Women and Child Development, Government of India. Menstrual Hygiene Scheme: Operational Guidelines. New Delhi: MWCD; 2013.
Sharma A, Taneja DK, Sharma P, Saha R. Problems related to menstruation amongst adolescent girls. Indian J Pediatr. 2008;75(7):669-672.
Desai RM, Shinde RR. A community based study on menstrual health among adolescent girls. Indian J Matern Child Health. 2011;13(3):1-6.
Singh MM, Devi R, Gupta SS, et al. An epidemiological study of adolescent health in an urban slum of Delhi. Indian J Med Sci. 1997;51(8):312-317.
Radha S, Vijayalakshmi S, Anantha E, et al. Prevalence of dysmenorrhea and its impact on school performance and attendance among adolescent girls in rural South India. Int J Community Med Public Health. 2016;3(8):2121-2126.
Ahuja A, Sharma MK, Chaudhary S. Epidemiological correlates of menstrual problems in adolescent girls in Chandigarh, India. Indian J Med Sci. 2006;60(12):485-491.
Sachdeva G, Sharma K, Raizada N, et al. Prevalence of polycystic ovary syndrome in Indian adolescents. J Pediatr Adolesc Gynecol. 2018;31(5):538-543.
Radha S, Vijayalakshmi S, Anantha E, et al. Prevalence of polycystic ovarian syndrome among adolescent girls in a rural area of South India. Int J Reprod Contracept Obstet Gynecol. 2016;5(10):3493-3496.
Swaminathan S, Thomas T, Kurpad AV. Dietary factors that determine the bioavailability of iron. Indian J Med Res. 2013;138(5):852-857.
Thankachan P, Muthayya S, Walczyk T, et al. Iron absorption in young Indian women: the interaction of iron status with the influence of tea and ascorbic acid. Am J Clin Nutr. 2008;87(4):881-886.
Federation of Obstetric and Gynaecological Societies of India (FOGSI). Consensus Statement on Management of Abnormal Uterine Bleeding. Mumbai: FOGSI; 2017.
Munro MG, Critchley HO, Broder MS, Fraser IS. FIGO working group on menstrual disorders. FIGO classification system (PALM-COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age. Int J Gynaecol Obstet. 2011;113(1):3-13.
Fraser IS, Critchley HO, Broder M, Munro MG. The FIGO recommendations on terminologies and definitions for normal and abnormal uterine bleeding. Semin Reprod Med. 2011;29(5):383-390.
Lethaby A, Duckitt K, Farquhar C. Non-steroidal anti-inflammatory drugs for heavy menstrual bleeding. Cochrane Database Syst Rev. 2013;(1):CD000400.
Lethaby A, Augood C, Duckitt K, Farquhar C. Nonsteroidal anti-inflammatory drugs for heavy menstrual bleeding. Cochrane Database Syst Rev. 2007;(4):CD000400.
Marjoribanks J, Lethaby A, Farquhar C. Surgery versus medical therapy for heavy menstrual bleeding. Cochrane Database Syst Rev. 2006;(2):CD003855.
Gupta J, Kai J, Middleton L, et al. Levonorgestrel intrauterine system versus medical therapy for menorrhagia. N Engl J Med. 2013;368(2):128-137.
Kaunitz AM, Meredith T, Inki P, et al. Levonorgestrel-releasing intrauterine system and endometrial ablation in heavy menstrual bleeding: a systematic review and meta-analysis. Obstet Gynecol. 2009;113(5):1104-1116.
Indian Council of Medical Research (ICMR). Guidelines on Diagnosis and Management of Polycystic Ovary Syndrome. New Delhi: ICMR; 2017.
Legro RS, Arslanian SA, Ehrmann DA, et al. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2013;98(12):4565-4592.